[Standard-of-care systemic therapy with or without SBRT in patients with oligoprogressive breast cancer or NSCLC (CURB oligoprogression): an open-label, randomised, controlled, phase 2 study].
Florian StritzkeThomas HeldPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2024)
Keyphrases
- small cell lung cancer
- radiation therapy
- healthcare
- open label
- quality improvement
- study protocol
- advanced non small cell lung cancer
- pain management
- affordable care act
- randomized controlled trial
- stem cells
- double blind
- placebo controlled
- brain metastases
- mesenchymal stem cells
- young adults
- epidermal growth factor receptor